Brevan Howard Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Brevan Howard Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.9K	Sell	13,098 -26,346	-67%	-$160K	﹤0.01%	2015
2026 Q1	$303K	Sell	39,444 -9,456	-19%	-$87.7K	﹤0.01%	1611
2025 Q4	$559K	Buy	48,900 +33,597	+220%	+$342K	0.01%	1048
2025 Q3	$141K	Buy	+15,303	New	+$111K	﹤0.01%	1824
2024 Q2	–	Sell	-88,483	Closed	-$835K	–	1166
2024 Q1	$835K	Buy	+88,483	New	+$790K	0.01%	315

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brevan Howard Capital Management's FULC Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 67% in Q2 2026, selling an estimated $160K and leaving 13,098 shares worth $47.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Brevan Howard Capital Management first reported a position in FULC in Q1 2024 and has held it in 5 quarters since. The position peaked at $835K in Q1 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Brevan Howard Capital Management held 13,098 shares of Fulcrum Therapeutics worth $47.9K as of Q2 2026.
Brevan Howard Capital Management sold 26,346 Fulcrum Therapeutics shares in Q2 2026, an estimated $160K.
Fulcrum Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2015 holding.
Brevan Howard Capital Management first reported a position in Fulcrum Therapeutics in Q1 2024 and has held it in 5 quarters since.
Brevan Howard Capital Management's Fulcrum Therapeutics position peaked at $835K in Q1 2024.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.